Skip to main content
. 2021 Apr 5;22(7):3764. doi: 10.3390/ijms22073764

Figure 5.

Figure 5

Plasma adenosine deaminase (ADA) activity in breast cancer patients. The activity of total ADA (tADA), ADA1, and ADA2 in healthy controls (n = 18); estrogen (ER) and progesterone (PR) receptor positive, HER2 positive (HR+ HER2+ BC, n = 12); ER and PR positive, HER2 negative (HR+ HER2- BC, n = 16); and triple negative (TNBC, n = 19) breast cancer patients (A); in HR+ HER2+ BC/ HR+ HER2- BC/ TNBC patients with different stages of cancer development (I stage: n = 3/7/7; II stage: n = 6/4/5; III stage: n = 3/4/7) (B). Results are shown as mean ± SEM, * p < 0.05, ** p < 0.01, *** p < 0.0001, **** p < 0.00001 by one-way ANOVA followed by Holm-Sidak post hoc test (A, C, and D) and Kruskal-Wallis test followed by Dunn’s post hoc test (B).